Clinical
RSSArticles
-
Society of Family Planning Issues Clinical Recommendation for Medication Abortion
As maternity and OB/GYN deserts spread across the United States, medication abortion to expel the fetus and placenta from the uterus without a surgical procedure is possible and can work safely and well between 14 weeks and nearly 28 weeks of gestation. There are few absolute contraindications to medication abortion from 14 to 27 weeks of gestation, according to the Society of Family Planning and Society of Maternal-Fetal Medicine’s new clinical recommendation.
-
Patients May Desire Contraception Even When Ambivalent About Pregnancy Within a Year
Asking patients about their pregnancy intention might not be the best barometer for whether they want contraception. New research revealed that women who had not had sex with a man in the last month or longer, women who said they wanted to become pregnant in the next year, and women who were ambivalent about preventing pregnancy also said they wanted contraception now.
-
The ACA’s Contraceptive Mandate Is Failing to Ensure Free Access to LARC
The Affordable Care Act mandates employers and payers to provide free contraception, including long-acting reversible contraception. But the authors of a new study found that the proportion of people paying $0 for most contraceptive methods declined between 2014 and 2020.
-
What Do We Need to Learn About Oral Contraceptives?
In this Q&A, Elizabeth Hampson, PhD, a professor in the department of psychology and core member of the graduate program in neuroscience at Western University in London, Canada, discussed what is needed in reproductive health research.
-
Research Sheds Light on Depression, Cognitive Issues, and Hormonal Contraception
More research is needed to learn how hormonal contraceptives affect the brain — both cognition and depression. Recent studies suggest some actions that may be beneficial.
-
A New Intervention Criterion for Ascending Aortic Aneurysm
A large retrospective study from the Yale University Aortic Institute database of unoperated patients with ascending thoracic aneurysms has shown that the risk of an adverse aortic event rises significantly at 5.0 cm to 5.4 cm in maximum diameter and supports moving the guideline for surgical intervention from 5.5 cm to 5.0 cm.
-
Anti-Ischemic Therapy for Microvascular Angina
A small, invasive study of coronary microvascular disease patients has shown that those with a coronary flow reserve < 2.5 may benefit from anti-ischemic therapy.
-
Atorvastatin vs. Rosuvastatin in Patients with Coronary Artery Disease
A large trial of moderate doses of rosuvastatin vs. atorvastatin in patients with coronary artery disease has shown that both drugs are equivalent at reducing major adverse cardiovascular and cerebral events, but rosuvastatin is associated with higher rates of new- onset diabetes and cataract surgery.
-
Apixaban vs. Aspirin for Subclinical Atrial Fibrillation
A randomized controlled trial of apixaban vs. low-dose aspirin therapy for subclinical atrial fibrillation detected by implanted electrophysiologic devices showed that apixaban is associated with fewer strokes, but more major bleeding episodes compared to aspirin.
-
Percutaneous Coronary Intervention vs. Placebo for Stable Angina Patients
In this randomized trial of patients with stable angina and objective evidence of ischemia, percutaneous coronary intervention resulted in a significant reduction in angina compared to a placebo procedure.